Feldman SR, et al. - In biologic-naïve and biologic-experienced patients in the US, experts assessed the cost-effectiveness of brodalumab vs ustekinumab for treating moderate-to-severe psoriasis. Findings suggested an association of treatment with brodalumab vs ustekinumab with better cost-effectiveness ratios for biologic-naïve and experienced-patients, and also patients with and without prior biologic treatment failure. For biologic-experienced and prior biologic treatment failure patients, the greater cost-effectiveness of brodalumab was most prominent.